Phreesia, Inc. — FY2021 Form 10-K
Reporting period: Fiscal year ended January 31, 2021, compared with fiscal 2020 ended January 31, 2020. Although the request identifies 2020 Q4, this filing is an annual report; it does not provide a clear standalone fourth-quarter financial summary.
Business context and performance
Phreesia provides a SaaS platform for healthcare patient intake, payments and engagement, alongside targeted digital marketing for life sciences companies. In fiscal 2021, it served over 1,800 provider organizations, facilitated nearly $2.0 billion in patient payments and reported an average of 1,711 revenue-generating provider clients.
Key financial metrics
| Metric | FY2021 | FY2020 | Change |
|---|---|---|---|
| Revenue | $148.7 million | $124.8 million | +19% |
| Subscription and related services | $69.0 million | $56.4 million | +23% |
| Payment processing fees | $49.9 million | $46.5 million | +7% |
| Life sciences | $29.7 million | $21.9 million | +36% |
| Operating loss | $(25.7) million | $(15.3) million | Loss widened |
| Net loss | $(27.3) million | $(20.3) million | Loss widened |
| Adjusted EBITDA (non-GAAP) | $3.8 million | $4.8 million | Down from prior year |
| Cash provided by operating activities | $2.9 million | $0.8 million | Increased |
| Free cash flow (non-GAAP) | $(15.7) million | $(11.5) million | More negative |
| Cash and cash equivalents at year-end | $218.8 million | $90.3 million | Increased |
Operating loss margin was approximately negative 17% and net loss margin approximately negative 18% in FY2021, based on reported revenue and losses. Adjusted EBITDA margin was approximately 2.6%, calculated from reported figures; it is a non-GAAP measure. Patient payment volume increased 7% to $1.997 billion. Average revenue per provider client rose 6% to $69,499.
Investing cash use was $25.1 million, including $11.2 million of property and equipment purchases, $7.3 million of capitalized software costs and $6.5 million for QueueDr, net of cash acquired. Financing provided $150.7 million, principally from the October 2020 stock offering. The company reported no borrowings under its $50 million revolving credit facility at year-end. Total debt and finance lease liabilities were $11.3 million, largely finance leases. Management said cash, normal-course cash generation and available credit were expected to fund operations for at least 12 months.
Material changes versus FY2020
- Revenue grew across all reported streams. Management attributed subscription growth to new clients and expansion and cross-selling to existing clients; life sciences growth to new programs and deeper outreach.
- Payment processing revenue grew despite COVID-19-related reductions in patient visits; management cited client growth and increased patient financial responsibility as offsets.
- Operating expenses rose 24% to $174.3 million. Sales and marketing and general and administrative expenses each increased 33%, principally reflecting higher compensation and headcount. Net loss widened, while Adjusted EBITDA declined.
- Cash increased substantially following the October 2020 public offering, which generated approximately $174.8 million in net proceeds before third-party offering costs. The company repaid its revolving facility balance in December 2020.
- Average provider clients increased 9%. The company acquired QueueDr in January 2021 for total estimated consideration of $10.1 million, including contingent consideration, to strengthen its appointment solutions.
Outlook, risks and unusual items
- Outlook: No quantified revenue, earnings or cash-flow guidance is provided in the supplied filing text. Management expects continued investment in product development, sales capacity and growth, and aims to improve margins over time; it also expects net losses and negative cash flows to continue for at least the next year.
- COVID-19: Patient visits returned to pre-pandemic levels in Q3 FY2021 and remained stable in Q4 despite a surge in cases. Management cautioned that pandemic effects remained uncertain. Its COVID-19 screening module was used in over 45 million screenings during the year.
- Financial reporting controls: Management and the auditor identified a material weakness involving user and privileged access and program change management for IT systems supporting financial reporting. The auditor issued an adverse opinion on internal control effectiveness. The financial statement audit opinion was unqualified; management reported no material financial statement misstatements from the weakness. Remediation was ongoing.
- Other risks: The filing highlights the risk of continued losses, variable sales and implementation cycles, reliance on payment processing and third-party providers, competition including from EHR/PM partners, sensitive-data privacy and security obligations, healthcare regulation, client retention and concentration, and the effects of healthcare-sector consolidation.
- Contingencies and unusual items: QueueDr contingent consideration was $1.3 million at year-end, with a maximum remaining amount of $1.5 million. No pending legal proceedings were reported as expected to have a material adverse effect. A $54.6 million valuation allowance was recorded against deferred tax assets.
Important facts for investors to verify
- Confirm the annual-period results against the audited statements; this 10-K does not supply standalone 2020 Q4 figures.
- Track whether the IT access and change-management material weakness is remediated and controls are tested as effective.
- Assess whether revenue growth can translate into improved GAAP operating results and free cash flow as expenses and investment rise.
- Monitor COVID-19 effects on provider visits, payment volume, client implementations and life sciences campaigns.
- Review payment processor and supplier dependencies, facility covenants, finance lease obligations and QueueDr contingent payments.